Medical Devices — US PTAB Patent Cases
112 decisions indexed
Page 1 of 4 · 112 total
BTL Industries, Inc. v.InMode Ltd.
BTL Industries successfully navigated the institution phase of an IPR against InMode Ltd.'s medical device patent (8961511). The Board adopted a specialized skill level for the POSA and preliminarily constructed key terms related to RF energy application in gynecological tissue.
Therabody, Inc. v.Hyperice IP Subco, LLC et al.
Therabody challenged Hyperice's patent on percussive massagers based on indefiniteness and obviousness, but the PTAB upheld the claims. The Board found that key terms like 'substantially cylindrical' were supported by functional limitations in the specification.
Jeisys Medical Inc. et al. v.Serendia, LLC
The PTAB instituted an IPR challenging claims 13 and 14 of Serendia's patent, finding a reasonable likelihood of anticipation by the prior art reference Mehta. The case moves to trial phase after rejecting arguments for discretionary denial based on competitor relationships.
Aesthetic Management Partners, LLC et al. v.HydraFacial LLC
The USPTO Board granted institution of Inter Partes Review (IPR2025-01169), allowing the petitioner to proceed to trial against the challenged patent.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care Inc.'s IPR challenge against DexCom's glucose monitoring patent was instituted by the PTAB. The Board found a reasonable likelihood of success on anticipation and obviousness grounds over prior art reference Gross, despite acknowledging examination complexity. This decision advances Abbott's efforts to invalidate key claims in the medical device space.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care Inc. successfully petitioned to institute IPR against DexCom, Inc.'s glucose monitoring patent (11020031). The Board found sufficient evidence for trial on 22 claims based on anticipation and obviousness over prior art from Zhang and Shin.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott challenges DexCom's CGM patent (US 10375222) in an IPR, asserting that the claims are obvious over multiple prior art combinations. The petition was instituted by the Board after finding compelling evidence of unpatentability.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care Inc. successfully secured institutional status in an IPR against DexCom, Inc., regarding continuous glucose monitoring systems. The Board found sufficient evidence that prior art references anticipate or render obvious key claims related to transcutaneous sensors and drift profiles.
BTL Industries, Inc. v.InMode Ltd.
The PTAB issued a final written decision rejecting all 58 claims of the patent owner's application. The Board found that the Petitioner failed to meet its burden of proof regarding obviousness over combinations of prior art references (Edwards, Mosher, Ingle, Ollivier).
ResMed Corp. v.Cleveland Medical Devices, Inc.
ResMed Corp. successfully petitioned for institution of its IPR against Cleveland Medical Devices, Inc.'s patent covering CPAP systems. The Board declined discretionary denial, finding that the petitioner adequately demonstrated a reasonable likelihood of prevailing on both 102 and 103 grounds.
Ilooda Co., Ltd. et al. v.Serendia, LLC
Ilooda Co. challenges Serendia's patent (10869812) in an IPR based on anticipation and obviousness, focusing on microneedling technology. The petitioner argues that prior art references like Mehta render multiple claims unpatentable through various combinations of elements.
Aesthetic Management Partners, LLC et al. v.HydraFacial LLC
The USPTO granted institution for IPR2025-01217, allowing the trial to proceed after determining the petitioner had a reasonable likelihood of prevailing. This decision is part of a larger set of institutional rulings.
Catalyst OrthoScience Inc. v.Shoulder Innovations, Inc.
Catalyst OrthoScience Inc.'s Post-Grant Review petition against Shoulder Innovations, Inc. was denied by the PTAB. The Board found that Petitioner failed to establish a 'compelling merits' showing for either obviousness (103) or indefiniteness (112).
Therabody, Inc. v.Hyperice IP Subco, LLC et al.
Therabody, Inc. successfully convinced the PTAB to institute proceedings against Hyperice IP Subco, LLC regarding a medical device patent (11857482). The Board found prima facie evidence of obviousness and indefiniteness across multiple claims based on prior art combinations.
Catalyst OrthoScience Inc. v.Shoulder Innovations, Inc.
The PTAB denied Catalyst OrthoScience's Post-Grant Review of Shoulder Innovations' reverse shoulder implant patent (12,023,254). The denial was based on the advanced stage and significant overlap with co-pending district court litigation.
Dexcom, Inc. v.Abbott Diabetes Care Inc.
Dexcom, Inc. filed a Petition challenging claims 1, 13, and 29 of Abbott Diabetes Care Inc.'s patent (US 11298056). The challenger asserts that these claims are obvious under 35 U.S.C. § 103 based on combinations of prior art references like Patel-2009 and Paradigm® REAL-Time. This petition also argues against discretionary denial, asserting the arguments are new and diligent.
BTL Industries, Inc. v.InMode Ltd.
BTL Industries successfully petitioned to challenge InMode Ltd.'s patent on urogenital tissue tightening methods. The PTAB found compelling merits in the petition, leading to institution of the IPR proceedings.
Cala Health, Inc. v.EMKinetics, Inc.
Cala Health challenges the validity of EMKinetics' '669 patent by asserting that its claims are anticipated or obvious over prior art references, primarily Gesotti and Burnett. The petitioner argues that the claimed technology for tremor treatment is already disclosed in the prior art, presenting multiple grounds under 35 U.S.C. §§ 102 and 103.
NULIDS, LLC v.BlephEx, LLC
NULIDS challenges BlephEx's patent (11083621) in an IPR petition, arguing that the device for ocular disorder treatment is obvious. The petitioner relies on combinations of prior art references including Grenon I, Grenon II, Nichamin, Colin, and Shabo to invalidate claims 1-6, 9-18.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care Inc. challenged DexCom's CGM needle insertion claims in an IPR, asserting that the anti-rotation features are anticipated or rendered obvious by prior art references like Pace, Chae, and Lundquist. The petitioner argues various combinations of these disclosures render numerous claimed features obvious under 35 U.S.C. §§102 and 103.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care Inc. challenged DexCom, Inc.'s '625 patent claims in a PTAB proceeding, asserting that the claims are obvious under 35 U.S.C. § 103. The petitioner argues that numerous features of the patented technology are rendered obvious either by single prior art references (Rao) or combinations involving Rao and Lundquist. Additionally, Abbott questions the written description support for key anti-rotation features.
Biofrontera AG et al. v.Sun Pharmaceutical Industries, Inc.
Biofrontera AG et al. challenged U.S. Patent No. 11,697,028 held by DUSA Pharmaceuticals, Inc., alleging obviousness under 35 U.S.C. § 103. The challenge focuses on the combination of prior art references to demonstrate that specific Photodynamic Therapy (PDT) illuminator claims are unpatentable.
SHENZHEN ROOT TECHNOLOGY CO., LTD. et al. v.Chiaro Technology Ltd.
Shenzhen Root Technology Co., Ltd. has filed a Petition challenging U.S. Patent No. 11,413,380 held by Chiaro Technology Ltd. The challenge centers on obviousness (Section 103), arguing that the claimed features of the breast pump are combinations of existing prior art references like Chang, Weber, and Guthrie.
Solventum Corporation v.M.E.A.C. Engineering Ltd.
Solventum Corporation filed a petition challenging 22 claims of the '534 Patent owned by M.E.A.C. Engineering Ltd., asserting that they are anticipated under 35 U.S.C. § 102. Petitioner argues that the prior art reference, Bitel (WO 03/030966), discloses every element of the claimed negative pressure wound therapy system.
Medela LLC et al. v.M.E.A.C. Engineering Ltd.
Medela LLC has filed an Inter Partes Review petition challenging key patents related to Negative Pressure Wound Therapy (NPWT) systems held by M.E.A.C. Engineering Ltd. The petitioner asserts that the challenged claims are unpatentable based on anticipation and obviousness using multiple prior art references.
Medela LLC et al. v.M.E.A.C. Engineering Ltd.
Medela LLC filed a Petition challenging 22 claims of patent 8858534 related to Negative Pressure Wound Therapy (NPWT). The petitioners assert grounds of anticipation and obviousness based on combinations of prior art references, including Risk, Watson, Hunt, Lina, and Dolliver. The petition was successfully instituted by the Board.
Imperative Care, Inc. v.INARI MEDICAL, INC.
Imperative Care, Inc. filed an IPR challenging INARI MEDICAL, INC.'s patent on Intravascular Catheter Valves. The petitioner asserts that the claims are anticipated by Schaffer or rendered obvious through combinations of Hartley and Eller.
Avanos Medical, Inc. v.Stratus Medical, LLC
Avanos Medical filed a Petition challenging Stratus Medical's RF neurotomy needle patent ('782 Patent). The central argument is that the claimed device is obvious because it merely combines conventional features from prior art references like Racz, Fitz, and Lee. This challenges 27 claims related to advanced medical ablation technology.
Avanos Medical, Inc. v.Stratus Medical, LLC
Avanos Medical challenged Stratus Medical's RF neurotomy needle patent, arguing that the claimed deployable filament features are obvious.
Avanos Medical, Inc. v.Stratus Medical, LLC
Avanos Medical challenges Stratus Medical's RF neurotomy needle claims at the PTAB, asserting obviousness under 35 U.S.C. § 103. The Petitioner argues that combining multiple prior art references—including Racz, Fitz, and Lee—would have motivated a Person of Ordinary Skill in the Art to create the claimed device.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.